Dynavax's Possible Hep B Win Could Prove a Threat to GlaxoSmithKline

GlaxoSmithKline plc (NYSE:GSK) generates more than $1.2 billion per quarter selling vaccines that are used to treat infectious disease, and one of GlaxoSmithKline's top-selling vaccines is Engerix-B, a vaccine used to prevent the spread of hepatitis B.

Last quarter, Engerix-B helped generate $194 million in GlaxoSmithKline hepatitis vaccine revenue. However, Engerix-B's revenue stream could be in jeopardy if the FDA gives a go-ahead to Dynavax Technologies Corporation's (NASDAQ:DVAX) HEPLISAV-B, a new hepatitis B vaccine that may work better than Engerix-B.

Back to news